Replimune Group, Inc. (REPL) stock
REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$21.78−1.50 (-6.44%)
Close on Nov 11, 2026Market cap $2.06BP/E –Yield –
Replimune gross margin
Gross margin is gross profit as a percentage of revenue.
No gross margin figures for Replimune
Replimune has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?